Clinical Trials Directory

Trials / Completed

CompletedNCT00140543

European Trial of Immunosuppression in SPK Tx

A European Multicenter Open-Label Randomised Trial to Evaluate the Efficacy and Safety of Sirolimus and Tacrolimus Compared to MMF and Tacrolimus With Short-Course Induction Therapy, Short-Term Steroids Application in de Novo SPK Transplanted Diabetic Patients

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
228 (planned)
Sponsor
EUROSPK Study Group · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

1. To determine and compare the efficacy of Tacrolimus/Rapa versus Tacrolimus/MMF-based immunosuppression (in conjunction with initial short-term steroids and polyclonal antibody administration) in Type 1-diabetic patients undergoing simultaneous pancreas/kidney allograft transplantation. 2. To evaluate the safety of Tacrolimus/Rapa versus Tacrolimus/MMF in terms of drug-related complications and overimmunosuppression-associated complications, particularly under monitoring of the pharmacokinetic profile of all drugs administered.

Detailed description

This will be a controlled, randomised study, to be performed in 15-20 pancreas transplantation centers throughout Europe. Patients will be randomised into one of two treatment groups. Group 1 will receive Tacrolimus and Mycophenolate Mofetil (= best group in EuroSPK001 trial). Group 2 will receive Tacrolimus and Sirolimus. Both groups will receive in association short-term corticosteroids and polyclonal antibody preparation. Patients will be randomly assigned to one of the 2 treatment groups in a 1:1 ratio before transplantation. The study will last 3 years, with a first interim analysis of the data at 6 months and a complete analysis at 1 year.

Conditions

Interventions

TypeNameDescription
DRUGsirolimus versus mycophenolate mofetil

Timeline

Start date
2002-02-01
Completion
2005-09-30
First posted
2005-09-01
Last updated
2021-08-23

Locations

14 sites across 7 countries: Austria, Belgium, Czechia, Germany, Israel, Spain, Switzerland

Source: ClinicalTrials.gov record NCT00140543. Inclusion in this directory is not an endorsement.